Phase
Condition
Opioid Use Disorder
Stimulant Use Disorder
Treatment
DBS of the NAc
Clinical Study ID
Ages 22-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion criteria
Male and females age ≥ 22 years with diagnosis of opioid use disorder (OUD) based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) with at least a 5-year history
OUD must be the primary disorder
History of ongoing or previous opioid use, relapse, and/or cravings, despite attempts at, or attendance in, at least two different treatment modalities. These modalities may include: Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient COAT, residential treatment, inpatient treatment, alternative to intensive outpatient programs, Drug Dependence Unit programs, medication-assisted treatment (MAT), medication assisted recovery (MAR), inpatient or outpatient rehabilitation, detox programs, Narcotics Anonymous, individual or group therapy, Partial Hospitalization Programs (PHP), Sober living homes, or similar interventions.
Self-reports ongoing opioid cravings.
Has completed a neuro-psychological evaluation to the satisfaction of a neuropsychologist
Has completed a psychiatric evaluation to the satisfaction of a psychiatrist
Has had a brain MRI performed and reviewed by neurosurgeon with no contraindication for DBS procedure identified
Platelet count > 125,000 per cubic mm and prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits
Negative blood cultures to rule out bacteremia
Exclusion criteria
Prior brain surgery
Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or moderate risk of suicide based upon a score of 3 or greater on the Columbia Suicide Severity Scale, unless clinical judgment indicates that the individual is appropriate for inclusion despite these scores.
History of uncontrolled or persistent seizures
Suspected dementia based on neuropsychological screening or Mini Mental State Exam (MMSE) Score < 25
Contraindications for MRI:
Presence of implanted electrical stimulation device or other implanted metal devices (excluding dental braces).
Claustrophobia
Body weight exceeding limit of the machine (180 kg/400 lb)
Females who are pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test during the pre-op phase and must agree to utilize adequate birth control throughout the trial and for at least 30 days following trial completion.
Coagulopathy secondary to chronic need for anticoagulation medicine (e.g. warfarin) or anti-platelet medication (e.g. aspirin or clopidogrel)
Diagnosis of neurological disorders (e.g. multiple sclerosis, Parkinson's disease, and stroke)
Severe brain atrophy or presence of subdural hygromas or subdural hematomas on brain MRI
Any evidence of underlying endocarditis.
Primary language other than English
Have any other medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment.
Study Design
Study Description
Connect with a study center
AHN Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
United StatesSite Not Available
AHN Allegheny General Hospital
Pittsburgh 5206379, Pennsylvania 6254927 15212
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.